Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Schizophrenia and osteoporosis.

Mike Lean1, Goedele De Smedt

  • 1Department of Human Nutrition, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK. mej.lean@clinmed.gla.ac.uk

International Clinical Psychopharmacology
|April 23, 2004
PubMed
Summary

Antipsychotic-induced hyperprolactinaemia is not proven to independently increase osteoporosis risk in schizophrenia patients. Comprehensive medical assessment is crucial for managing bone health in these individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re: Interpreting the cost-effectiveness of diabetes remission programmes beyond the durability of remission.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Rationale and design of a parallel randomised trial of a plant-based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt-based weight loss InteRvention (REPAIR) trial.

Diabetes, obesity & metabolism·2026
Same author

Baseline Characteristics in the Remote Diet Intervention to REduce long-COVID Symptoms Trial (ReDIRECT).

NIHR open research·2024
Same author

Clinical outcomes and adverse events of bariatric surgery in adults with severe obesity in Scotland: the SCOTS observational cohort study.

Health technology assessment (Winchester, England)·2024
Same author

Prediction of Cardiometabolic Health Through Changes in Plasma Proteins With Intentional Weight Loss in the DiRECT and DIADEM-I Randomized Clinical Trials of Type 2 Diabetes Remission.

Diabetes care·2023
Same author

Navigating data governance approvals to use routine health and social care data to evidence the hidden population with severe obesity: a case study from a clinical academic's perspective.

Journal of research in nursing : JRN·2022

Area of Science:

  • Psychiatry
  • Endocrinology
  • Bone Metabolism

Background:

  • Antipsychotic medications can elevate prolactin levels (hyperprolactinaemia).
  • Hyperprolactinaemia has been hypothetically linked to osteoporosis in schizophrenia.
  • Schizophrenia patients face multifactorial risks for osteoporosis.

Purpose of the Study:

  • To investigate if antipsychotic-induced hyperprolactinaemia is an independent risk factor for osteoporosis in schizophrenia.
  • To clarify the relationship between hyperprolactinaemia and bone density in this patient population.

Main Methods:

  • Review of existing evidence and studies on schizophrenia, antipsychotics, hyperprolactinaemia, and osteoporosis.
  • Analysis of potential mechanisms linking hyperprolactinaemia to bone health in men and women.

Related Experiment Videos

Main Results:

  • Current evidence does not support antipsychotic-induced hyperprolactinaemia as an independent osteoporosis risk factor in schizophrenia.
  • Osteoporosis risk in women with antipsychotic-induced amenorrhoea is plausible, but no clear mechanism exists for men.
  • Schizophrenia itself and associated lifestyle factors contribute significantly to osteoporosis risk.

Conclusions:

  • Antipsychotic-induced hyperprolactinaemia is unlikely to be a primary driver of osteoporosis in schizophrenia.
  • Thorough medical and metabolic evaluation is essential for psychiatric patients to monitor bone health.
  • Further research may be needed to fully elucidate complex risk factors for osteoporosis in schizophrenia.